SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 8, 2006--Hana Biosciences (NASDAQ:HNAB - News): Hana Biosciences (NASDAQ:HNAB - News), a biopharmaceutical company focused on advancing cancer care, completed its previously announced licensing transaction with Inex Pharmaceuticals Corporation (TSX:IEX - News). Under the terms of the transaction, Hana paid INEX a total of $11.5 million, consisting of cash and shares of Hana common stock. In addition, Hana will pay INEX up to $30.5 million in shares of Hana common stock, contingent upon achievement of specific clinical and regulatory milestones, as well as royalties on net sales. Canaccord Adams acted as the exclusive financial advisor to Hana in the transaction.
